Blood Cancer Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Blood cancers are malignancies of the blood, bone marrow, and lymphatic system, broadly classified into leukaemias (cancers of immature blood cell precursors in the bone marrow, releasing abnormal cells into the blood), lymphomas (cancers of lymphoid tissue — lymph nodes, spleen, and extranodal sites), and plasma cell dyscrasias including multiple myeloma (malignant proliferation of antibody-producing plasma cells in the bone marrow). Together, these constitute the fourth most common cancer type globally, with approximately 1.3 million new cases per year.

Blood cancers are diverse diseases with distinct biologies, natural histories, and treatment strategies. Leukaemias include acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML), and chronic lymphocytic leukaemia (CLL). Lymphomas are classified as Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) — encompassing over 60 distinct subtypes including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, T-cell lymphomas, and Burkitt lymphoma.

All blood cancer diagnoses and treatment plans are managed by specialist haematology-oncology teams, discussed at multidisciplinary team meetings, and treated at designated cancer centres. Bone marrow trephine biopsy and aspirate, immunophenotyping by flow cytometry, cytogenetics (karyotype and FISH), and molecular profiling (next-generation sequencing for somatic mutations) are essential components of the diagnostic workup that define the specific disease subtype and guide treatment selection.

Acute myeloid leukaemia (AML) requires intensive induction chemotherapy (typically cytarabine + anthracycline — '7+3' regimen or variants) followed by consolidation chemotherapy or allogeneic stem cell transplantation (SCT) depending on cytogenetic and molecular risk stratification. FLT3, IDH1/2, and NPM1 mutations now direct targeted therapy additions (midostaurin, enasidenib, venetoclax) that have transformed outcomes. Acute lymphoblastic leukaemia (ALL) in adults is treated with intensive multi-agent combination chemotherapy regimens followed by maintenance and CNS prophylaxis; BCR-ABL1-positive ALL benefits enormously from tyrosine kinase inhibitor (TKI) addition (dasatinib, ponatinib).

Chronic myeloid leukaemia (CML) is now a largely chronic-manageable condition following the revolutionary introduction of imatinib (Gleevec) in 2001 — the first targeted kinase inhibitor in oncology — and subsequent generations (dasatinib, nilotinib, bosutinib, ponatinib, asciminib). Most patients achieve deep molecular remission on TKIs and many are eligible for treatment discontinuation (treatment-free remission). Hodgkin lymphoma is one of the most curable cancers, achieving 5-year overall survival of 85–90% with ABVD or BEACOPP chemotherapy plus radiotherapy. Diffuse large B-cell lymphoma (DLBCL) — the most common NHL — achieves complete remission in approximately 60–70% of patients with R-CHOP chemoimmunotherapy.

Treatment eligibility for blood cancer depends on the specific diagnosis, disease stage and risk stratification, patient performance status and organ function, age, comorbidities, and the availability of suitable donors for allogeneic SCT. Molecular and cytogenetic profiling determines risk category and directs treatment intensity: for AML, adverse-risk cytogenetics (monosomy 7, del(5q), complex karyotype) strongly favour allogeneic SCT consolidation, while favourable-risk disease (inv(16), t(15;17) — APL) achieves long-term remission with chemotherapy-only strategies.

Intensive induction chemotherapy is appropriate for fit patients with good performance status (ECOG 0–2) and adequate organ function. Reduced-intensity conditioning (RIC) allogeneic SCT extends transplant eligibility to older patients (up to age 70–75 at specialist centres). Novel low-intensity regimens combining venetoclax with azacitidine have transformed treatment of older/unfit AML patients, achieving complete remission rates of 66% in Phase III trials versus 22% with azacitidine alone, making curative-intent treatment accessible to previously untreatable patients.

Chemotherapy regimens for blood cancers are complex, multi-drug combination protocols administered in defined cycles. For ALL, paediatric-inspired regimens (UKALL, CALGB 10403) using vincristine, steroids, anthracyclines, asparaginase, and multiple consolidation blocks achieve complete remission in 85–95% of adults, with subsequent MRD (minimal residual disease) monitoring by PCR or flow cytometry guiding decisions about allogeneic SCT.

Allogeneic stem cell transplantation (SCT) — infusion of haematopoietic stem cells from a matched sibling or unrelated donor after conditioning chemotherapy ± radiotherapy — is the only potentially curative option for many high-risk haematological malignancies, leveraging the graft-versus-leukaemia (GVL) immunological effect alongside myeloablative conditioning. CAR-T cell therapy (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel) is now approved for relapsed/refractory DLBCL, mantle cell lymphoma, ALL, and multiple myeloma, achieving complete remissions in 30–50% of heavily pre-treated patients. Bispecific antibodies (blinatumomab, mosunetuzumab, epcoritamab) represent an exciting off-the-shelf alternative to personalised CAR-T therapy, showing high efficacy in relapsed lymphomas.

Selecting the most appropriate Blood Cancer Treatment approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Blood cancer outcomes have been transformed over the past two decades by molecular targeted therapies and novel immunological approaches. CML is now managed as a chronic disease — with TKI therapy, approximately 85–90% of patients achieve major molecular response and life expectancy approaches that of the general population. APL (a subtype of AML) achieves 5-year survival exceeding 90% with all-trans retinoic acid (ATRA) and arsenic trioxide-based regimens.

Hodgkin lymphoma achieves 5-year overall survival of 87% across all stages, making it one of the most curable solid and haematological malignancies. Paediatric ALL achieves cure rates of 85–90% with modern protocols. Autologous SCT consolidation for myeloma significantly improves progression-free survival. Novel triplet and quadruplet combinations (daratumumab + lenalidomide + bortezomib + dexamethasone) are producing complete response rates above 50% in transplant-eligible myeloma patients in Phase III trials. The introduction of venetoclax, polatuzumab vedotin, loncastuximab tesirine, and bispecific antibodies is continuing to improve outcomes in relapsed/refractory lymphomas.

Intensive chemotherapy causes myelosuppression — profound reduction in red blood cells, white blood cells, and platelets — requiring blood and platelet transfusions, growth factor support (G-CSF), and prophylactic antimicrobials (antibacterial, antifungal, antiviral). Febrile neutropenia — fever with severe neutropenia — is a medical emergency requiring immediate hospitalisation, blood cultures, and broad-spectrum IV antibiotics. Treatment-related mortality from infection, bleeding, or organ toxicity is approximately 5–10% in intensive AML induction programmes.

Allogeneic SCT carries significant risks including graft-versus-host disease (GVHD) — where donor immune cells attack recipient tissues — affecting the skin, gut, and liver. Acute GVHD occurs in 30–50% of patients and chronic GVHD (affecting 30–70% of survivors) causes long-term organ damage and immune compromise. Transplant-related mortality ranges from 5–20% depending on donor match, patient age, and conditioning intensity. Long-term survivors of intensive chemotherapy and SCT are at risk of treatment-related secondary malignancies (including MDS/AML from prior chemotherapy), cardiac toxicity from anthracyclines, and endocrine late effects.

During intensive chemotherapy, patients are hospitalised on haematology units with protective isolation, regular full blood counts, biochemistry, and infection monitoring. Allogeneic SCT patients remain hospitalised for 4–8 weeks until engraftment is confirmed and they are able to tolerate oral medications and nutrition. After discharge, twice-weekly outpatient clinic attendance for blood counts, immunosuppressant level monitoring (for SCT patients), and supportive care continues for 3–6 months.

Long-term follow-up includes regular MRD monitoring by PCR (CML, ALL, AML — specific mutations), PET-CT surveillance for lymphoma, M-protein monitoring for myeloma, and screening for late treatment effects. CML patients on TKIs with sustained deep molecular response are eligible for TKI discontinuation trials under specialist monitoring — approximately 40–60% of eligible patients achieve treatment-free remission. Psychosocial support, rehabilitation, and return-to-work planning are integral components of haematological cancer survivorship care.

Blood cancer treatment is extraordinarily expensive in high-income countries. Intensive AML induction chemotherapy with hospitalisation costs USD 50,000–150,000 in the US. Allogeneic SCT costs USD 200,000–500,000 or more. CAR-T cell therapy is priced at USD 400,000–600,000 per infusion. TKI therapy for CML costs USD 100,000–200,000 per year for branded agents (imatinib generics have dramatically reduced CML treatment costs). Myeloma triplet/quadruplet regimens including daratumumab cost USD 200,000–400,000 per year.

India has emerged as one of the most important global destinations for haematological cancer treatment, offering a combination of high-quality specialist haematology-oncology programmes and dramatically lower costs. Allogeneic SCT at JCI-accredited centres including Tata Memorial Hospital, Christian Medical College Vellore, Apollo Hospitals, and Narayana Health costs USD 20,000–50,000 — 75–85% less than US prices — with comparable outcomes. Generic imatinib (Gleevec biosimilar) is available in India for USD 100–300 per month versus USD 5,000–10,000 per month in the US. India's biosimilar cancer drug landscape offers profound cost advantages for patients from high-drug-cost countries.

For some blood cancers, watchful waiting or active surveillance is appropriate before initiating treatment. Asymptomatic early-stage CLL without indicators for treatment may be safely observed for years before specific therapy is required, as early treatment does not improve survival in low-risk CLL. Similarly, low-grade follicular lymphoma (grade 1–2) in asymptomatic patients may be managed with watch-and-wait, with treatment deferred until disease progression, transformation, or symptom development.

Palliative care and symptom management are appropriate for patients with refractory or incurable blood cancers who have exhausted standard treatment options or who choose not to pursue further intensive therapy. Enrolment in clinical trials of novel agents (including next-generation CAR-T constructs, antibody-drug conjugates, bispecific antibodies, and epigenetic therapies) is an important option for patients with relapsed/refractory disease, potentially offering access to promising experimental treatments before regulatory approval.